Avacta announces AVA6000 dose escalation results by John Pinching | Jun 21, 2023 | News | 0 Candidate is a cancer therapy that has been chemically modified with Avacta’s pre|CISION platform Read More
Avacta announces clinical study of AVA6000 by John Pinching | Sep 1, 2022 | News | 0 Pro-doxorubicin will advance to the fourth dose following a positive review of safety and tolerability Read More